Avadel Pharmaceuticals plc (AVDL)
NASDAQ: AVDL · Real-Time Price · USD
8.41
-0.06 (-0.71%)
At close: Feb 21, 2025, 4:00 PM
8.37
-0.04 (-0.47%)
After-hours: Feb 21, 2025, 4:43 PM EST
Avadel Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Avadel Pharmaceuticals stock have an average target of 18.86, with a low estimate of 12 and a high estimate of 30. The average target predicts an increase of 124.26% from the current stock price of 8.41.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Avadel Pharmaceuticals stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Deutsche Bank | Deutsche Bank | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +42.69% | Feb 11, 2025 |
| UBS | UBS | Strong Buy Maintains $22 → $14 | Strong Buy | Maintains | $22 → $14 | +66.47% | Jan 13, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $24 → $13 | Buy | Maintains | $24 → $13 | +54.58% | Jan 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 → $21 | Strong Buy | Reiterates | $25 → $21 | +149.70% | Jan 10, 2025 |
| Needham | Needham | Strong Buy Maintains $22 → $19 | Strong Buy | Maintains | $22 → $19 | +125.92% | Jan 9, 2025 |
Financial Forecast
Revenue This Year
172.11M
from 27.96M
Increased by 515.49%
Revenue Next Year
256.19M
from 172.11M
Increased by 48.85%
EPS This Year
-0.51
from -2.00
EPS Next Year
0.08
from -0.51
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 177.5M | 267.5M | 386.9M | |||
| Avg | 172.1M | 256.2M | 338.6M | |||
| Low | 165.3M | 241.9M | 270.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 534.6% | 55.4% | 51.0% | |||
| Avg | 515.5% | 48.9% | 32.2% | |||
| Low | 491.2% | 40.6% | 5.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.48 | 0.19 | 1.06 |
| Avg | -0.51 | 0.08 | 0.70 |
| Low | -0.53 | -0.04 | 0.14 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | 1,213.9% |
| Avg | - | - | 761.2% |
| Low | - | - | 70.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.